TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11182177
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no tablet)
Study: 9862942
Drug: Omeprazole plus
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole plus Amoxicillin and Clarithromycin (20 mg omeprazole twice daily, 1000 mg amoxicillin twice daily, 500 mg clarithromycin twice daily for 7 days)
Study: 28526386
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg/d) plus pyridoxine (80 mg/d)
Study: 23771563
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human albumin (2.5 g) in the extracorporeal prime
Study: 16684825
Drug: Teriparatide 37
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide 37 microg sc daily (group 2)
Study: 16684825
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (group 3)
Study: 16684825
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg daily (group 1)
Study: 11743672
Drug: Propofol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3 mg/kg and 10 mg/kg/h) in 60 % N2O/O2
Study: 3580514
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg q.i.d. for 4 days)
Study: 23408591
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injections (2 autologous injections over 2 weeks)
Study: 23408591
Drug: Focused extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Focused extracorporeal shock wave therapy (ESWT) (3 sessions of 2400 impulses at 0.17-0.25 mJ/mm² per session)
Study: 18644934
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplement containing vitamin A, folic acid, iron, zinc, and 11 other nutrients
Study: 17121726
Drug: Huperzine A
Normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine A (0.3 mg/2 ml)
Study: 10648365
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of nebulised budesonide (Bud)
Study: 8870326
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of diclofenac
Study: 8870326
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of diclofenac + 10 mg of prednisolone
Study: 6349134
Drug: Cytoplasmatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoplasmatic therapy with macromolecular substances
Study: 29304798
Drug: Short message
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short message service (SMS) reminders for dosing of artemether-lumefantrine (AL)
Study: 26779990
Drug: Ultrasonic lithotripsy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic lithotripsy (US-L)
Study: 20150299
Drug: Medication-taking behaviors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-taking behaviors
Study: 8284109
Drug: EPO 150
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO 150 U/kg s.c. twice weekly for 6 weeks
Study: 29319910
Drug: Nicotine (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (21 mg transdermal)
Study: 29319910
Drug: Galantamine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (16 mg oral)
Study: 29319910
Drug: Mecamylamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (30 mg oral)
Study: 24155873
Drug: Graded exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded exercise treatment
Study: 22114896
Drug: Societal costs
Normalized name: costus root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Societal costs (medication, other healthcare, productivity)
Study: 8849376
Drug: rHuIL‐1RI at
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuIL‐1RI at smaller doses (125, 250, 500 micrograms/m2/day)
Study: 8849376
Drug: rHuIL‐1RI (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuIL‐1RI (all doses)
Study: 1317234
Drug: Carvedilol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (50 mg p.o.)
Study: 1317234
Drug: Prazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (2 mg p.o.)
Study: 31757774
Drug: ETVAX (5·5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETVAX (5·5 × 10^10 cells, 2·5 × 10^10 cells, or 1·25 × 10^10 cells) with or without dmLT (2·5 μg, 5·0 μg, or 10·0 μg)
Study: 27556488
Drug: Watermelon (WM)
DrugBank: Watermelon (DB10578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon (WM) puree, 980 mL/day for 2 weeks, containing 0.2 gm/kg carbohydrate
Study: 20728652
Drug: Alcohol intoxication
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intoxication (0.08 g/dl)
Study: 14522623
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 0.05% cream
Study: 14522623
Drug: Hydrocortisone butyrate
Normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone butyrate (HCB) 0.1% cream
Study: 10972598
Drug: Milrinone (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (loading dose of 20 microg/kg followed by infusion of 0.2 microg/kg/min) in low pre-CPB CI group
Study: 10972598
Drug: Milrinone (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (loading dose of 20 microg/kg followed by infusion of 0.2 microg/kg/min) in high pre-CPB CI group
Study: 1482134
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of TIBO (100 mg for 29 days)
Study: 1482134
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of TIBO (100 mg, 200 mg, and 100 mg with probenecid daily for 14 days)
Study: 6531024
Drug: 8‐MOP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8‐MOP plus TMP (combination dose)
Study: 6531024
Drug: Low-dose 8‐MOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose 8‐MOP (0.3 mg/kg)
Study: 6531024
Drug: 8‐MOP or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8‐MOP or combination group of 8‐MOP plus TMP
Study: 6531024
Drug: High-dose TMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TMP and psoralen
Study: 31909382
Drug: TAP Block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP Block with USG guidance using 0.25% bupivacaine 60 ml (30 ml at each side)
Study: 31909382
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl 60 ml (30 ml at each side) with USG guidance (Control Group)
Study: 18679600
Drug: Weicao Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weicao Capsule (WCC)
Study: 18679600
Drug: Tongfengding Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongfengding Capsule (Control)
Study: 16003661
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) using treatment-based classification guidelines
Study: 12452739
Drug: Glibenclamide/metformin 2.5/500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide/metformin 2.5/500mg tablets (Glucovance)
Study: 12452739
Drug: Glibenclamide 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide 2.5mg with metformin 500mg (Micronase + Glucophage)
Study: 7555001
Drug: Quinidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (250 mg) + Diazepam (10 mg)
Study: 7555001
Drug: Quinidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (250 mg) alone
Study: 25362844
Drug: High-dose rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rate brachytherapy (2×10 Gy) and external beam radiotherapy (25×2 Gy)
Study: 23040208
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate 70 mg once weekly
Study: 21555984
Drug: Conventional Occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Occupational Therapy and Conventional Gait Training
Study: 12150179
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri DSM 12246, 10(10) colony-forming units of each strain twice daily for 5 days
Study: 12150179
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri DSM 12246, 10(10) colony-forming units of each strain twice daily for 5 days (early intervention)
Study: 1972847
Drug: Intradermal injections
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injections of PPD (1 in 1000)
Study: 1972847
Drug: Intradermal injections
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injections of streptokinase/streptodornase (20 mu/5 mu per 0.1 ml)
Study: 1972847
Drug: Saline control
Normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control solutions
Study: 28554606
Drug: CAPI (interviewer-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPI (interviewer-administered comprehensive health and social risk assessments)
Study: 28554606
Drug: ACASI (self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACASI (self-administered comprehensive health and social risk assessments)
Study: 23432801
Drug: SP monthly
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP monthly and azithromycin (1 g) twice (AZI-SP)
Study: 23432801
Drug: SP monthly
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP monthly (monthly SP)
Study: 16709205
Drug: Vaginal clindamycin
Normalized name: clindamycin Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal clindamycin treatment
Study: 14998423
Drug: Tramadol LP
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol LP 200 mg
Study: 14998423
Drug: Tramadol LP
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol LP 200 mg (fasting state)
Study: 14998423
Drug: Tramadol LP
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol LP 200 mg (fed state)
Study: 6849741
Drug: Indoramin 100
Normalized name: indoramin
DrugBank: Indoramin (DB08950)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin 100 mg
Study: 6849741
Drug: Indoramin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (all doses)
Study: 30552587
Drug: LCPT 0.17
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPT 0.17 mg/kg/day (n = 37)
Study: 30552587
Drug: PR-Tac 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-Tac 0.20 mg/kg/day (n = 38)
Study: 26941199
Drug: PICN 260
Approvals — FDA: no, EMA: no, PMDA: no
Description: PICN 260 mg/m2
Study: 26941199
Drug: PICN 295
Approvals — FDA: no, EMA: no, PMDA: no
Description: PICN 295 mg/m2
Study: 26941199
Drug: nab-paclitaxel 260
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 260 mg/m2
Study: 22495466
Drug: Revascularization plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revascularization plus standard medical therapy
Study: 18404122
Drug: omega-6 fatty
Normalized name: Omega-6 Fatty Acids
DrugBank: Omega-6 fatty acids (DB13168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-6 fatty acids treatment before and after PRK
Study: 906784
Drug: Gallamine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallamine 0.4 mg/kg
Study: 906784
Drug: Gallamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallamine 0.5 mg/kg
Study: 31768936
Drug: 4-Methylpyrazole (4-MP)
Normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-Methylpyrazole (4-MP) administered intravenously alongside APAP.
Study: 31768936
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) alone without 4-MP.
Study: 27872357
Drug: Ibuprofen (IBU)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (IBU) pediatric suspension 7.5 mg/kg
Study: 27872357
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) suspension 10 to 15 mg/kg
Study: 26124203
Drug: Siltuximab (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab (11 mg/kg every 3 weeks)
Study: 15880316
Drug: Supportive enteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive enteral or parenteral nutrition (1000 kcal/d until patients did not wish to continue)
Study: 15880316
Drug: Supportive enteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive enteral or parenteral nutrition
Study: 15880316
Drug: Oral nutrition
Normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutrition only (control)
Study: 12865481
Drug: Weekly injections
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly injections of testosterone (T; 100 mg/week)
Study: 7612052
Drug: Oral racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral racemic propafenone preparation (300 mg)
Study: 2696433
Drug: Lactoferrin (L)
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin (L) added to formula
Study: 12151246
Drug: Neural manual
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neural manual therapy technique
Study: 12151246
Drug: Indirect manual
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect manual therapy techniques
Study: 12151246
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (crossed over to neural manual therapy after 8 weeks)
Study: 30174418
Drug: High-Intensity Laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Laser Therapy (HILT) of 1,064 nm, 60 J/cm2, 10 minutes
Study: 30174418
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT) of 785 nm, 8 J/cm2, 8 minutes
Study: 24751502
Drug: Levosimendan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.1 μg/kg/min continuous infusion for 24 h)
Study: 22810741
Drug: Thrombolysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis with standard therapy
Study: 20233178
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (42 mg/day)
Study: 12107600
Drug: Dofetilide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide (500 microg twice daily)
Study: 12107600
Drug: Sotalol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (160 mg twice daily)
Study: 352088
Drug: 5% guanethidine/1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% guanethidine/1% adrenaline combination
Study: 25986699
Drug: Waiting-list treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list treatment as usual control group
Study: 24183218
Drug: Topical adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical adenosine 0.75%
Study: 20024680
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg/valsartan 320 mg/hydrochlorothiazide 25 mg (triple therapy)
Study: 20024680
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg/hydrochlorothiazide 25 mg (dual therapy)
Study: 20024680
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg/valsartan 320 mg (dual therapy)
Study: 20024680
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg/hydrochlorothiazide 25 mg (dual therapy)
Study: 17219991
Drug: Clinical stages,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical stages, tumor complete capsule, and lymph node metastasis
Study: 12963991
Drug: Tegafur suppositories
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tegafur suppositories (750 mg/day) from 1 to 2 weeks prior to surgery, to 2 weeks following surgery, followed by oral administration of tegafur and uracil (UFT) (260 mg/m(2)) for 1 year
Study: 12963991
Drug: UFT (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (260 mg/m(2)) for 1 year beginning week 2 after surgery
Study: 1574257
Drug: Estrogen receptor
Normalized name: Estrogen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen receptor assay performed at the largest cross-section of a large tumor
Study: 1574257
Drug: Estrogen receptor
Normalized name: Estrogen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen receptor assay performed on a small random part of a large tumor
Study: 4081525
Drug: Interferon nasal
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon nasal spray (IFN-alpha), 50,000 IU per day, sprayed twice a day.
Study: 27541801
Drug: Intravenous MTX
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous MTX (4 mg/kg) monthly for 5 months with folinic acid rescue 24 hours after MTX administration
Study: 16261288
Drug: Thrombolytic regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic regimen with half reteplase (r-PA) dose plus abciximab
Study: 16261288
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose r-PA
Study: 8699540
Drug: Psychosocial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatment interventions (4-month duration)
Study: 25733243
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg PO
Study: 25733243
Drug: S‐methyl‐l‐thiocitrulline (SMTC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐methyl‐l‐thiocitrulline (SMTC, 0.05, 0.1, and 0.2 μmol/min)
Study: 24455682
Drug: Triptolide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptolide (1 mg/kg · d) combined with prednisone (2 mg/kg · d) for 6 to 9 months
Study: 10694120
Drug: Creatine (CR)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (CR) loading (20 g x d(‐1) for 5 days)
Study: 8112803
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg zinc sulphate (elemental Zn 45 mg) orally/day
Study: 2461017
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Logiparin) 35 XaI mu/kg b.w. once daily for 7 days
Study: 31564231
Drug: 0.40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.40 mg/kg tenecteplase (max 40 mg)
Study: 31564231
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg tenecteplase (max 25 mg)
Study: 23916618
Drug: Mediolateral (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediolateral (ML) translations of the walking surface
Study: 16989200
Drug: Local cutaneous
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local cutaneous alpha therapy with radon applicator (7.4 Bq/l, 90 minutes)
Study: 8117358
Drug: 32 g
Normalized name: PEG-32 Glyceryl Laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 g sugar‐beet fibre/d
Study: 3494725
Drug: Nimorazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimorazole (2 g single dose)
Study: 27635617
Drug: Pantogam syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantogam syrup 10% (hopantenic acid)
Study: 20579955
Drug: Betamethasone administered
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone administered in a randomized controlled trial of weekly antenatal corticosteroids (ACS)
Study: 12889565
Drug: Percutaneous acetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous acetic acid injection (PAI) using 50% acetic acid
Study: 12889565
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection (PEI) using pure ethanol
Study: 10967901
Drug: Inspiratory resistive
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory resistive load (10 cmH2O/L/sec) during quiet breathing
Study: 9234616
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with ciprofloxacin (CPFX) and clarithromycin (CAM), 600 mg/day for 14 days
Study: 9234616
Drug: Single therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single therapy with ciprofloxacin (CPFX), 600 mg/day for 14 days
Study: 28007405
Drug: Ephedrine 50
Normalized name: Ephedrine 50 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 50 mg daily in 2 doses
Study: 25999694
Drug: SYP‐1018 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYP‐1018 (200 mg)
Study: 25999694
Drug: Vfend(®) (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vfend(®) (200 mg)
Study: 7935028
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose hormone replacement (0.3 mg/day equine estrogen and 2.5 mg/day medroxyprogesterone)
Study: 7935028
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose hormone replacement (0.625 mg/day equine estrogen, days 1‐25, and 5 mg/day medroxyprogesterone, days 16‐25)